LONDON, United Kingdom — After years of clinical trial failures, an anti-interferon antibody, anifrolumab, has been shown to dramatically reduce disease activity in extrarenal systemic lupus ...
Investigators studied expression of type I interferons, key pathogenic drivers in systemic lupus erythematosus and lupus nephritis.
Scientists have discovered that some tiny segments of RNA thought to be junk instead have a functional role in suppressing production of certain messenger RNAs and appear to help cells respond to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results